Numerous pathologic conditions (e.g. cancer, osteoporosis, arthritis, and fibrosis) are associated with excess collagen degradation mediated by distinct sets of proteases such as matrix metalloproteases (MMP), serine proteases, and cysteine proteases. Among them, cysteine cathepsins (cystein proteases) are considered one of the most important therapeutic targets as evidenced by various cathepsin knockout mice models. Although over 20 different types of cathepsin inhibitors have been developed, their on and/or off target cellular toxicity (lysosomotropic effect) has limited clinical use of these potenial drugs, and only a few are currently undergoing human trials. In light of recent findings that cathepsin's activity outside the cells are strongly associated with pathologic conditions, the ability to localize cathepsin inhibitor to extracellular spaces, in particular, to places where degradative activity is ongoing could lead to a breakthrough in clinical application of cathepsin and other protease inhibitors. This project will test the suitability of CMP as drug delivery agent for targeting degrading collagens in pathologic tissues, with particular focus on developing new synthetic conjugates of collagen mimetic peptide (CMP) and irreversible cathepsin K inhibitor. Overall objective of the proposed work is to explore the CMP mediated targeting capacity and therapeutic benefits of delivering irreversible cathepsin K (Cat-K) inhibitors to collagens undergoing degradation as related to developing anti-resorptive therapeutic agents for osteoporosis.
The proposed work explores the benefit of delivering therapeutic drugs to collagens that are undergoing fast remodeling. The targeting is based on recently discovered peptide hybridization mechanism (discovered in PI's group) that is highly specific to denatured/degraded collagens which are found in a wide variety pathologic tissues (e.g. cancers, arthritis, fibrosis). In particular, a new type of drug for osteoporosis is proposed based on collagen-targeting enzyme inhibitors.
|Converse, Matthew I; Walther, Raymond G; Ingram, Justin T et al. (2018) Detection and characterization of molecular-level collagen damage in overstretched cerebral arteries. Acta Biomater 67:307-318|
|Hwang, Jeongmin; Huang, Yufeng; Burwell, Timothy J et al. (2017) In Situ Imaging of Tissue Remodeling with Collagen Hybridizing Peptides. ACS Nano 11:9825-9835|
|Zitnay, Jared L; Li, Yang; Qin, Zhao et al. (2017) Molecular level detection and localization of mechanical damage in collagen enabled by collagen hybridizing peptides. Nat Commun 8:14913|
|San, Boi Hoa; Hwang, Jeongmin; Sampath, Sujatha et al. (2017) Self-Assembled Water-Soluble Nanofibers Displaying Collagen Hybridizing Peptides. J Am Chem Soc 139:16640-16649|
|Hwang, Jeongmin; San, Boi Hoa; Turner, Neill J et al. (2017) Molecular assessment of collagen denaturation in decellularized tissues using a collagen hybridizing peptide. Acta Biomater 53:268-278|
|Bennink, Lucas L; Smith, Daniel J; Foss, Catherine A et al. (2017) High Serum Stability of Collagen Hybridizing Peptides and Their Fluorophore Conjugates. Mol Pharm 14:1906-1915|
|San, Boi Hoa; Li, Yang; Tarbet, E Bart et al. (2016) Nanoparticle Assembly and Gelatin Binding Mediated by Triple Helical Collagen Mimetic Peptide. ACS Appl Mater Interfaces 8:19907-15|
|Wahyudi, Hendra; Reynolds, Amanda A; Li, Yang et al. (2016) Targeting collagen for diagnostic imaging and therapeutic delivery. J Control Release 240:323-331|
|Li, Yang; San, Boi Hoa; Kessler, Julian L et al. (2015) Non-covalent photo-patterning of gelatin matrices using caged collagen mimetic peptides. Macromol Biosci 15:52-62|
|Chan, Tania R; Stahl, Patrick J; Li, Yang et al. (2015) Collagen-gelatin mixtures as wound model, and substrates for VEGF-mimetic peptide binding and endothelial cell activation. Acta Biomater 15:164-72|
Showing the most recent 10 out of 11 publications